Skip to main content

Table 2 Detection rates of CTCs in 84 blood samples from 48 epithelial cancer patients and in 30 samples from 22 melanoma patients.

From: Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients

Carcinoma Number of blood samples Number of patients Positivity of blood samples Positivity of patients*
Gastric 5 3 80% (4/5) 67% (2/3)
Colon 25 11 44% (11/25) 64% (7/11)
Ovarian 8 6 50% (4/8) 50% (3/6)
Breast 21 10 52% (11/21) 60% (6/10)
Cervix 11 7 64% (7/11) 86% (6/7)
NSCLC 4 3 75% (3/4) 100% (3/3)
SCCHN 10 8 70% (7/10) 75% (6/8)
Melanoma 32 22 53% (17/32) 64% (14/22)
  1. NOTE: * A patient was defined as positive for detection of CTCs if at least one sample resulted to be positive for presence of CTCs.